Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAINMAX for Post-COVID Asthenia
NCT05689827Phase 4Completed
- Sponsor
- Promomed
- Start
- Apr 2022
- Primary completion
- Nov 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthenia comparing BRAINMAX with Placebo (2 arms). Primary endpoint: Multidimensional Fatigue Inventory at Day 41. Started Apr 2022; status: completed.
02
Drugs
Huperzine A
03
Conditions
asthenia
Beyond the preview
Go deeper on NCT05689827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689827.